Search
Smallpox (Vaccinia) Vaccine, Live
go.drugbank.com/drugs/DB14711ApprovedInvestigational[L12747] ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain.
AT2220
go.drugbank.com/drugs/DB05200InvestigationalAT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones. It is a small molecule designed to act as a pharmacological chaperone that specifically b...
Abaloparatide
go.drugbank.com/drugs/DB05084ApprovedInvestigational[L740] It was first approved by the FDA on April 28, 2017,[A256748] for the treatment of osteoporosis in postmenopausal women and is also used to increase bone density in men with osteoporosis. … L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized by
Glisoxepide
go.drugbank.com/drugs/DB01289Investigationalby sulphate. … Glisoxepide uptake could be further inhibited by blockers of the hepatocellular monocarboxylate transporter, by the loop diuretic bumetanide, by 4,4'-diisothiocyano-2,2'-stilbenedisulfonate (DIDS) and
Colesevelam
go.drugbank.com/drugs/DB00930ApprovedInvestigationalIt works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol.
Ximelagatran
go.drugbank.com/drugs/DB04898ApprovedWithdrawnXimelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former.
Huperzine A
go.drugbank.com/drugs/DB04864ApprovedInvestigationalWithdrawnIt is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease.
Imiglucerase
go.drugbank.com/drugs/DB00053ApprovedInvestigationalAlglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase.
PSN357
go.drugbank.com/drugs/DB05044ExperimentalPSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
Apixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalApixaban was approved by the FDA on December 28, 2012[L6043].